Posts by: Alejandra Viviescas, PhD.

Alejandra Viviescas, PhD.

Alejandra has a PhD in Genetics from São Paulo State University (UNESP) and is currently working as a scientific writer, editor, and translator. As a writer for BioNews, she is fulfilling her passion for making scientific data easily available and understandable to the general public. Aside from her work with BioNews, she also works as a language editor for non-English speaking authors and is an author of science books for kids.

December 4, 2019December 6, 2019

Relugolix Induces Sustained Testosterone Reduction in Advanced PC, HERO Phase 3 Trial Results Show

News

Treatment with Myovant Sciences’ relugolix induces a long-lasting reduction in testosterone to castrate levels — similar to testosterone levels after medical or chemical castration — in nearly all men with ... Read more

July 8, 2019

68Ga-PSMA-11 Better than Axumin at Detecting PC Recurrence, Trial Shows

News

Among men suspected of having prostate cancer recurrence after surgery, the radiotracer 68Ga-PSMA-11 is better at detecting the cancerous lesions and provides better agreement among experts than the standard Axumin ... Read more

June 24, 2019

FDA OKs Phase 2 Trial of Ampligen Combo as Pre-surgery PC Treatment

News

The U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase 2 clinical trial testing Hemispherx Biopharma‘s Ampligen (rintatolimod), in combination with aspirin or aspirin plus Intron ... Read more

June 19, 2019

FDA Grants Arvinas’ ARV-110 Fast Track Designation for mCRPC

News

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Arvinas‘ lead protein degrader ARV-110 to treat patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has ... Read more

May 16, 2019

Xtandi Better, Cheaper than Zytiga for Treatment of mCRPC, Study Suggests

News

Treating chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients with Xtandi (enzalutamide) leads to better survival outcomes and lower healthcare costs than Zytiga (abiraterone acetate), a study suggests. The findings were ... Read more

April 18, 2019

Liquid Biopsy Test Helping Select People with Advanced Prostate Cancer for Phase 2 Study of Pamiparib

News

A Phase 2 trial testing the investigational PARP inhibitor pamiparib in treating metastatic castration-resistant prostate cancer patients is using Epic Sciences‘ novel liquid biopsy assay to select those patients who are ... Read more

January 21, 2019

SmartTarget Improves Prostate Cancer Detection During Biopsies, Study Says

News

SmartTarget, an image fusion software that combines magnetic resonance imaging (MRI) and ultrasounds, should be used along with a visual review of MRI scans to conduct biopsies in patients with ... Read more

November 15, 2018

Radiation and Hormone Therapy Combo May Help Prevent Cancer’s Return After Prostatectomy

News

Prostate cancer patients who show signs of disease progression after surgery to remove the prostate may benefit by combining standard therapy with short-term androgen deprivation (STAD) and pelvic lymph node radiation therapy ... Read more

November 1, 2018

Certain Prostate Cancer Patients May Benefit From Higher Radiation Doses in Fewer Sessions, Study Shows

News

Stereotactic body radiation therapy (SBRT) — a kind of radiation therapy that delivers high doses of radiation over a shorter treatment course — is as safe and effective as the ... Read more

October 31, 2018October 31, 2018

Baseline PSA Screening During Midlife Predicts Prostate Cancer in Black Men, Study Finds

News

Measuring PSA levels during midlife — between 40 and 64 years — could help predict the likelihood an African-American man has of developing prostate cancer up to 12 years after ... Read more